Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

Abhinav Mathur; Joakim Edman; Livia Liang; Neil Scott; Henry Watson

doi:10.1002/jha2.551

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

Abhinav Mathur^* (Corresponding Author), Joakim Edman, Livia Liang, Neil Scott, Henry Watson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.

Original language	English
Pages (from-to)	1305-1309
Journal	eJHaem
Volume	3
Issue number	4
Early online date	2 Sept 2022
DOIs	https://doi.org/10.1002/jha2.551
Publication status	Published - 20 Nov 2022

Bibliographical note

Funding Information
This research was supported by NHS Grampian Endowment Fund (grant number: EA4075).

Data Availability Statement

The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Additional supporting information can be found online in the Supporting Information section at the end of this article.

Keywords

essential thrombocythaemia
hydroxycarbamide
melanoma
myeloproliferative neoplasm
non-melanoma skin cancer
polycythemia vera

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jha2.551Licence: CC BY

Mathur_etal_JH_Skin_Cancer_In_VoR
This is an open access article under the terms of the Creative Commons Attribution License, which permits use ,distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/
Final published version, 153 KBLicence: CC BY

Cite this

@article{2d11d8ba09a24434a2da1e3dec2ed3e2,

title = "Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide",

abstract = "Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.",

keywords = "essential thrombocythaemia, hydroxycarbamide, melanoma, myeloproliferative neoplasm, non-melanoma skin cancer, polycythemia vera",

author = "Abhinav Mathur and Joakim Edman and Livia Liang and Neil Scott and Henry Watson",

note = "Funding Information This research was supported by NHS Grampian Endowment Fund (grant number: EA4075).",

year = "2022",

month = nov,

day = "20",

doi = "10.1002/jha2.551",

language = "English",

volume = "3",

pages = "1305--1309",

journal = "eJHaem",

issn = "2688-6146",

publisher = "John Wiley & Sons, Ltd",

number = "4",

}

TY - JOUR

T1 - Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

AU - Mathur, Abhinav

AU - Edman, Joakim

AU - Liang, Livia

AU - Scott, Neil

AU - Watson, Henry

N1 - Funding Information This research was supported by NHS Grampian Endowment Fund (grant number: EA4075).

PY - 2022/11/20

Y1 - 2022/11/20

N2 - Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.

AB - Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.

KW - essential thrombocythaemia

KW - hydroxycarbamide

KW - melanoma

KW - myeloproliferative neoplasm

KW - non-melanoma skin cancer

KW - polycythemia vera

U2 - 10.1002/jha2.551

DO - 10.1002/jha2.551

M3 - Article

C2 - 36467813

SN - 2688-6146

VL - 3

SP - 1305

EP - 1309

JO - eJHaem

JF - eJHaem

IS - 4

ER -

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

Abstract

Bibliographical note

Data Availability Statement

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this